RxDoctor Payments DataLook up a doctor →

Saleemah Fahmi, MD

Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1922283506

Payments from drug & device makers

$1,166,734in general payments, 2019–2025

Across 2,793 payments — averaging $417.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$506K
  • Corcept Therapeutics$238K
  • Amgen$173K
  • Abbott$59K
  • Shire North American Group Inc$46K
  • AbbVie$31K
  • plus $115K from 44 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC981$505,930
Corcept Therapeutics349$237,604
Amgen(2 entities)321$172,669
Abbott156$58,543
Shire North American Group Inc68$46,446
AbbVie57$30,726
Sanofi-aventis U.S. LLC52$25,496
Xeris Pharmaceuticals, Inc.130$25,432
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC107$24,394
Boehringer Ingelheim53$17,515
Mannkind Corporation104$6,244
Novo Nordisk70$5,344
Johnson & Johnson11$2,820
Medtronic(2 entities)40$1,620
AstraZeneca(2 entities)59$1,351
Dexcom, Inc.27$678
Bayer26$549
Merck26$306
Sequel Med Tech, LLC14$304
Insulet Corporation16$295
Zealand Pharma US, Inc.16$271
IBSA Pharma Inc.13$222
Recordati_rare_diseases_inc.9$221
Amneal Pharmaceuticals LLC11$179
Madrigal Pharmaceuticals6$169
Amryt Pharma Holdings Ltd3$152
Neurocrine Biosciences, Inc.5$135
Ascendis Pharma Endocrinology Inc5$125
Novartis7$111
Esperion Therapeutics, Inc.5$84
Amarin Pharma, Inc.4$75
Intuity Medical Inc4$71
Currax Pharmaceuticals LLC5$70
Tandem Diabetes Care, Inc.4$69
Lifescan, Inc.5$64
BETA Bionics, Inc.4$63
Pfizer4$61
Cequr Corporation3$56
Ultragenyx Pharmaceutical Inc.2$43
Janssen Scientific Affairs, LLC1$36
Gilead1$30
GSK1$26
Astellas Pharma US Inc1$24
Valeritas, Inc.1$21
Amphastar Pharmaceuticals, Inc.1$20
Rhythm Pharmaceuticals, Inc.1$16
Kyowa Kirin, Inc.1$15
Arbor Pharmaceuticals, Inc.1$14
Avvisto Therapeutics, LLC1$14
Vistapharm, Inc.1$13

How this compares

$1,166,734 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$173,515
Medicare patients
269
Services billed
1,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →